» Articles » PMID: 29016968

Formalizing Drug Indications on the Road to Therapeutic Intent

Overview
Date 2017 Oct 11
PMID 29016968
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent.

Citing Articles

The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.

Lago S, Bahn S NPJ Genom Med. 2022; 7(1):25.

PMID: 35338153 PMC: 8956592. DOI: 10.1038/s41525-022-00290-4.


InContext: curation of medical context for drug indications.

Moodley K, Rieswijk L, Oprea T, Dumontier M J Biomed Semantics. 2021; 12(1):2.

PMID: 33579375 PMC: 7881657. DOI: 10.1186/s13326-021-00234-4.


A bottom-up approach to creating an ontology for medication indications.

Nelson S, Flynn A, Tuttle M J Am Med Inform Assoc. 2021; 28(4):753-758.

PMID: 33484128 PMC: 7973454. DOI: 10.1093/jamia/ocaa331.


Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.

Cheng C, Salazar A, Amato M, Lambert B, Volk L, Schiff G J Am Med Inform Assoc. 2018; 25(7):872-884.

PMID: 29800453 PMC: 7647046. DOI: 10.1093/jamia/ocy043.

References
1.
Gottlieb A, Stein G, Ruppin E, Sharan R . PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011; 7:496. PMC: 3159979. DOI: 10.1038/msb.2011.26. View

2.
Carter J, Brown S, Erlbaum M, Gregg W, Elkin P, Speroff T . Initializing the VA medication reference terminology using UMLS metathesaurus co-occurrences. Proc AMIA Symp. 2002; :116-20. PMC: 2244264. View

3.
Rappaport N, Twik M, Plaschkes I, Nudel R, Iny Stein T, Levitt J . MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2016; 45(D1):D877-D887. PMC: 5210521. DOI: 10.1093/nar/gkw1012. View

4.
Kuhn M, Letunic I, Jensen L, Bork P . The SIDER database of drugs and side effects. Nucleic Acids Res. 2015; 44(D1):D1075-9. PMC: 4702794. DOI: 10.1093/nar/gkv1075. View

5.
Nelson S, Zeng K, Kilbourne J, Powell T, Moore R . Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011; 18(4):441-8. PMC: 3128404. DOI: 10.1136/amiajnl-2011-000116. View